RESEARCH MONOGRAPH · KDC-MN-308

Nicergoline

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

64/100

The cleaner single-molecule ergoloid that quietly outperformed Hydergine, still a respectable cerebrovascular agent

Nicergoline (Sermion) is the ergoloid that Farmitalia developed in the late 60s as a single-molecule alternative to the Hydergine mixture, and honestly the pharmacology is cleaner than Hydergine in most ways. It's a 10-methoxy-1,6-dimethyl-ergoline-8-beta-methanol nicotinate ester. The nicotinate ester is the structural feature that distinguishes it from the rest of the ergoloid class.

The mechanism is more focused than Hydergine. Nicergoline is a potent alpha-1A adrenergic antagonist (selective for the subtype that drives most vascular smooth muscle constriction) with additional activity on dopamine and serotonin receptors that's pharmacologically less prominent than the alpha-1 effect. Downstream you get cerebrovascular vasodilation, improvement of cerebral blood flow, and there's a meaningful literature on direct effects on cholinergic neurotransmission and NGF signaling that gives nicergoline a different profile than the simple vasodilator story would suggest.

The clinical evidence is more substantial than Hydergine's, particularly the Italian and German trials in vascular cognitive impairment. The most-cited recent meta-analysis (Fioravanti and Flicker, Cochrane review) concluded probable benefit in cognitive function and behavior in elderly patients with vascular dementia or mixed dementia, with a more consistent effect size than hydergine. The Italian Nicergoline Cooperative Group work in the 90s is the more methodologically rigorous body of trials.

What we like: cleaner pharmacology than Hydergine, more consistent clinical trial signal, and a mechanism profile that does something interesting beyond the simple cerebrovascular vasodilation. The cholinergic and NGF effects in animal models are real and underdiscussed.

What we dont love is the regulatory wrinkle. Nicergoline is registered in much of Europe but the EMA Article 31 review in 2014 restricted the cerebrovascular and cognitive indications based on concerns about ergot-related fibrosis risk shared with other ergoline derivatives. The restriction was disputed by clinicians (the dihydro-ergot fibrosis profile is different from the cabergoline/pergolide picture) but the regulatory state has stayed restrictive in some markets.

Sourcing is okay. Pharma-grade nicergoline exists in European markets, research-grade material is available with reasonable QC, and the molecule is reasonably stable. The nicotinate ester is the QC item to verify because hydrolysis to the parent alcohol is the typical degradation pathway.

Evidence: 65
Mechanism: 70
Reliability: 65
Safety: 70
Sourcing: 65
Value: 65
Signal: 55
Staying power: 55

Plain-language summary Intrigue 40 / 100

Nicergoline (Sermion) is a semisynthetic ergoline developed at Farmitalia in Italy and approved across Europe for cerebrovascular disease and age-related cognitive decline. It blocks alpha-1 adrenergic receptors (causing cerebral vessel dilation), inhibits platelet aggregation, and has weak cholinergic effects. Some studies suggested mild improvements in memory and behavior in dementia patients, but the evidence base is heavily Eastern European and methodologically uneven. It is no longer marketed in the US and is rarely used in modern Western practice. Survives in nootropic communities and in markets that approved it long ago. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Ergoline derivative / alpha-1 antagonist + cerebrovascular agent

A semisynthetic ergoline derivative; an alpha-1 adrenergic antagonist with cerebrovascular and acetylcholinesterase modulatory activity.

Abstract

Nicergoline (10-alpha-methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; CAS 27848-84-6; molecular formula C24H26BrN3O3; molecular weight 484.39) is a semisynthetic ergoline developed at Farmitalia (Italy) and approved in several European countries under the trade name Sermion for cerebrovascular disease and age-related cognitive decline. Mechanism: alpha-1 adrenergic antagonism (cerebrovascular dilation), inhibition of platelet aggregation, weak nicotinic and muscarinic effects, and modulation of acetylcholinesterase activity in some studies. Plasma half-life is approximately 2 hours for the parent compound; the active metabolite 1,6-dimethyl-8-beta-hydroxymethyl-10-alpha-methoxy-ergoline (MMDL) has substantially longer half-life. Approved for cerebrovascular insufficiency in Europe; not approved in the US. Used as a reference ergoline cerebrovascular agent in research.

Mechanism of action

Alpha-1 adrenergic antagonism, cerebrovascular dilation; weak cholinergic modulation. Active metabolite MMDL extends duration.

Reported research dose ranges

Clinical 30 to 60 mg in the published literature.

References

Winblad B, et al. Therapeutic use of nicergoline. Clin Drug Investig 2008.
Battaglia A, et al. Nicergoline in mild to moderate dementia. J Int Med Res 1989.
Iliff LD, et al. Nicergoline pharmacology and clinical use. Eur J Drug Metab Pharmacokinet 2002.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-308

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Nicergoline

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs